Astellas Pharma Inc

4503

Company Profile

  • Business description

    Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

  • Contact

    2-5-1, Nihonbashi-Honcho
    Chuo-ku
    Tokyo103-8411
    JPN

    T: +81 332443000

    http://www.astellas.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 March 2026

    Employees

    13,643

Stocks News & Analysis

stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.
stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.80116.001.30%
CAC 407,866.0844.080.56%
DAX 4024,446.9676.030.31%
Dow JONES (US)44,484.49229.710.52%
FTSE 1008,993.0020.360.23%
HKSE24,825.66326.711.33%
NASDAQ20,885.65155.160.75%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,880.4025.01-0.19%
S&P 5006,297.3633.660.54%
S&P/ASX 2008,757.20118.201.37%
SSE Composite Index3,534.4817.660.50%

Market Movers